Request Your Free Data Sheet Now:

"A novel RNA polymerase variant for reduced dsRNA byproducts in mRNA manufacturing"

As mRNA therapeutics expand into cancer vaccines, cell therapies and beyond, manufacturing high-quality mRNA with minimal byproducts is more critical than ever.

This poster explores how a novel RNA polymerase can help you reduce double-stranded RNA (dsRNA) byproducts during mRNA manufacturing, improving the tolerability, safety, and potency of potential mRNA therapies.   

Key data presented: 

• Achieve dsRNA reduction by up to 85% in in vitro transcription (IVT)  
• Lower dsRNA levels in both mRNA and saRNA syntheses without impacting quality attributes 
• Integrate effortlessly into existing IVT protocols with simple enzyme substitution 

Offered Free by: TriLink
See All Resources from: TriLink